Pim J French

List of Publications by Citations

99 papers	7,150 citations	40 h-index	84 g-index
118 ext. papers	9,406 ext. citations	8.1 avg, IF	5.32 L-index

#	Paper	IF	Citations
99	Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. *Journal of Clinical Oncology*, **2013**, 31, 344-50	2.2	800
98	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. *Lancet Oncology, The*, **2017**, 18, e315-e329	21.7	599
97	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. *Nature*, **2012**, 488, 49-56	50.4	596
96	Intertumoral Heterogeneity within Medulloblastoma Subgroups. *Cancer Cell*, **2017**, 31, 737-754.e6	24.3	511
95	Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. *Cancer Research*, **2009**, 69, 9065-72	10.1	437
94	Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. *Nature Genetics*, **2011**, 43, 1256-61	36.3	392
93	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. *Nature Reviews Clinical Oncology*, **2021**, 18, 170-186	19.4	204
92	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. *Lancet Oncology, The*, **2016**, 17, 484-495	21.7	187
91	Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?. *Lancet Oncology, The*, **2011**, 12, 83-91	21.7	167
90	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. *Acta Neuropathologica*, **2018**, 136, 153-166	14.3	162
89	Longitudinal molecular trajectories of diffuse glioma in adults. *Nature*, **2019**, 576, 112-120	50.4	151
88	The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. *Neuro-Oncology*, **2018**, 20, 103-112	1	142
87	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. *Acta Neuropathologica*, **2013**, 126, 917-29	14.3	115
86	IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. *Annals of Neurology*, **2011**, 69, 455-63	9.4	114
85	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. *Neuro-Oncology*, **2016**, 18, 388-400	1	102
84	Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. *Neuro-Oncology*, **2015**, 17, 935-41	1	98
83	Gene expression profiles associated with treatment response in oligodendrogliomas. *Cancer Research*, **2005**, 65, 11335-44	10.1	95

82	A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. *Clinical Cancer Research*, **2011**, 17, 7148-55	12.9	93
81	MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. *Clinical Cancer Research*, **2013**, 19, 5513-22	12.9	89
80	Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. *Human Mutation*, **2010**, 31, E1186-99	4.7	84
79	Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. *Journal of Clinical Oncology*, 2013, 31, 337-34	2.2	80
78	AT-34CONSTRUCTION OF AN INTEGRATED DIAGNOSTIC ALGORITHM CONSISTING OF CONSENSUS HISTOLOGIC AND MOLECULAR PARAMETERS OF TWO EORTC TRIALS ON ANAPLASTIC GLIOMA. *Neuro-Oncology*, **2014**, 16, v16-v16	1	78
77	Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. *Nature*, **2019**, 574, 707-711	50.4	78
76	ACTR-47. PATIENTS WITH EGFR AMPLIFICATION BUT WITHOUT EGFRvIII EXPRESSION HAVE IMPROVED BENEFIT COMPARED TO THOSE WITH EGFRvIII EXPRESSION IN SAMPLES OF THE INTELLANCE 2/EORTC 1410 RANDOMIZED PHASE II TRIAL. *Neuro-Oncology*, **2018**, 20, vi22-vi22	1	78
75	TMOD-25. MODELING IDH1-MUTATED GLIOMAS: GENERATION, CHARACTERIZATION AND THERAPEUTIC SENSITIVITIES OF SEVEN PATIENT-DERIVED IDH1-MUTANT GLIOMA CELL LINES. *Neuro-Oncology*, **2018**, 20, vi274-vi274	1	78
74	IMMU-62. LOW-GRADE GLIOMA EXCLUDE CD8 T CELLS, WHICH IS ACCOMPANIED BY LOW EXPRESSION OF CHEMO-ATTRACTANTS, NOT IMMUNOGENIC ANTIGENS. *Neuro-Oncology*, **2018**, 20, vi135-vi135	1	78
73	PATH-42. EGFR-AMPLIFIED IDH-WILDTYPE GLIOBLASTOMAS SELDOM TRANSFORM INTO A HYPERMUTATED PHENOTYPE. *Neuro-Oncology*, **2018**, 20, vi168-vi168	1	78
72	DRES-05. MOLECULAR EVOLUTION OF DIFFUSE GLIOMAS AND THE GLIOMA LONGITUDINAL ANALYSIS CONSORTIUM. *Neuro-Oncology*, **2018**, 20, vi76-vi76	1	78
71	DRES-14. PROTEIN AGGREGATE FORMATION PREDICTS CLINICAL RESPONSES TO EGFR TKIs. *Neuro-Oncology*, **2018**, 20, vi78-vi78	1	78
70	Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays. *Cancer Research*, **2007**, 67, 5635-42	10.1	77
69	Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. *Cancer Research*, **2016**, 76, 525-34	10.1	70
68	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. *Neuro-Oncology*, **2018**, 20, 873-884	1	63
67	Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors. *Advances in Anatomic Pathology*, **2013**, 20, 32-8	5.1	62
66	INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. *Neuro-Oncology*, **2020**, 22, 684-693	1	62
65	Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. *Acta Neuropathologica*, **2017**, 134, 957-959	14.3	61

64	Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. *Neuro-Oncology*, **2020**, 22, 515-523	1	58
63	Heterogeneity within the PF-EPN-B ependymoma subgroup. *Acta Neuropathologica*, **2018**, 136, 227-237	14.3	52
62	Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. *Lancet Oncology, The*, **2018**, 19, 1170-1179	21.7	49
61	Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays. *Journal of Molecular Diagnostics*, **2011**, 13, 634-47	5.1	44
60	Molecular Evolution of Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. *Journal of Clinical Oncology*, **2020**, 38, 81-99	2.2	43
59	Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm. *Clinical Cancer Research*, **2019**, 25, 7455-7462	12.9	40
58	Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules. *Neuro-Oncology*, **2013**, 15, 1684-95	1	39
57	Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives. *Cancers*, **2020**, 12,	6.6	36
56	Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives. *Cancers*, **2020**, 13,	6.6	33
55	PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. *Acta Neuropathologica Communications*, **2015**, 3, 88	7.3	27
54	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. *Lancet Oncology, The*, **2021**, 22, 813-823	21.7	24
53	Subgroup-specific alternative splicing in medulloblastoma. *Acta Neuropathologica*, **2012**, 123, 485-499	14.3	23
52	Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens. *Scientific Reports*, **2019**, 9, 14643	4.9	21
51	Molecular subtypes of glioma identified by genome-wide methylation profiling. *Genes Chromosomes and Cancer*, **2013**, 52, 665-74	5	21
50	Integrated genomic profiling identifies candidate genes implicated in glioma-genesis and a novel LEO1-SLC12A1 fusion gene. *Genes Chromosomes and Cancer*, **2010**, 49, 509-17	5	20
49	Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. *European Journal of Cancer*, **2018**, 94, 168-178	7.5	19
48	Genetic alterations in glioma. *Cancers*, **2011**, 3, 1129-40	6.6	19
47	Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics. *Acta Neuropathologica Communications*, **2018**, 6, 126	7.3	19

46	Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. *Journal of Neuro-Oncology*, **2011**, 103, 221-30	4.8	18
45	A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab. *Molecular Oncology*, **2016**, 10, 1296-304	7.9	17
44	TRiC controls transcription resumption after UV damage by regulating Cockayne syndrome protein A. *Nature Communications*, **2018**, 9, 1040	17.4	16
43	Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma. *Journal of Neuro-Oncology*, **2018**, 139, 349-357	4.8	15
42	Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas. *Cancers*, **2018**, 10,	6.6	14
41	Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation. *European Journal of Cancer*, **2015**, 51, 893-903	7.5	13
40	Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 Trials. *Journal of Clinical Oncology*, **2015**, 33, 1943-50	2.3	13
39	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. *Journal of Neuro-Oncology*, **2019**, 144, 205-210	4.8	13
38	Defining EGFR amplification status for clinical trial inclusion. *Neuro-Oncology*, **2019**, 21, 1263-1272	1	12
37	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. *Cell Reports Medicine*, **2020**, 1,	18	11
36	Unique intrahepatic transcriptomics profiles discriminate the clinical phases of a chronic HBV infection. *PLoS ONE*, **2017**, 12, e0179920	3.7	11
35	Absence of common somatic alterations in genes on 1p and 19q in oligodendrogliomas. *PLoS ONE*, **2011**, 6, e22000	3.7	11
34	Tumor-specific mutations in low-frequency genes affect their functional properties. *Journal of Neuro-Oncology*, **2015**, 122, 461-70	4.8	10
33	Exon expression arrays as a tool to identify new cancer genes. *PLoS ONE*, **2007**, 3, e3007	3.7	10
32	SMARCAD1-mediated active replication fork stability maintains genome integrity. *Science Advances*, **2021**, 7,	14.3	10
31	Lack of B and T cell reactivity towards IDH1 in blood and tumor tissue from LGG patients. *Journal of Neuro-Oncology*, **2019**, 144, 79-87	4.8	9
30	Structural and expression differences between the vasculature of pilocytic astrocytomas and glioblastomas. *Journal of Neuropathology and Experimental Neurology*, **2013**, 72, 1171-81	3.1	9
29	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. *Acta Neuropathologica*, **2021**, 141, 945-957	14.3	9

28	Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion.. *Journal of Clinical Oncology*, **2017**, 35, 2009-2009	2.2	8
27	A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling. *Prostate*, **2019**, 79, 937-948	4.2	7
26	The transcriptional landscape of Shh medulloblastoma. *Nature Communications*, **2021**, 12, 1749	17.4	7
25	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. *Neuro-Oncology*, **2021**, 23, 1547-1559	1	7
24	Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors. *Scientific Reports*, **2020**, 10, 2927	4.9	6
23	EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand. *Neuro-Oncology Advances*, **2020**, 2, vdz051	0.9	6
22	Beyond the Influence of Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma. *Cancers*, **2020**, 12,	6.6	6
21	Raman spectroscopy can discriminate distinct glioma subtypes as defined by RNA expression profiling. *Journal of Raman Spectroscopy*, **2013**, 44, 1217-1221	2.3	5
20	Essential role for Gata2 in modulating lineage output from hematopoietic stem cells in zebrafish. *Blood Advances*, **2021**, 5, 2687-2700	7.8	5
19	Differences in spatial distribution between WHO 2016 low-grade glioma molecular subgroups. *Neuro-Oncology Advances*, **2019**, 1, vdz001	0.9	4
18	Evidence-based management of adult patients with diffuse glioma - AuthorsR reply. *Lancet Oncology, The*, **2017**, 18, e430-e431	21.7	4
17	Prognostic stratification of adult primary glioblastoma multiforme patients based on their tumor gene amplification profiles. *Oncotarget*, **2018**, 9, 28083-28102	3.3	4
16	ACTR-11. SECOND INTERIM AND 1ST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CODELETION. *Neuro-Oncology*, **2019**, 21, vi14-vi14	1	4
15	Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer. *EBioMedicine*, **2021**, 73, 103681	8.8	3
14	IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis. *PLoS ONE*, **2018**, 13, e0199737	3.7	2
13	Single cell transcriptome analysis reveals an essential role for Gata2b in hematopoietic lineage decisions in zebrafish		2
12	Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures. *Neuro-Oncology Advances*, **2021**, 3, vdab103	0.9	2
11	Subgroup and subtype-specific outcomes in adult medulloblastoma. *Acta Neuropathologica*, **2021**, 142, 859-871	14.3	2

List of Publications

10	Fusion transcripts and their genomic breakpoints in polyadenylated and ribosomal RNA-minus RNA sequencing data. *GigaScience*, **2021**, 10,	7.6	2
9	MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas.. *Neuro-Oncology*, **2022**,	1	1
8	Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors. *EBioMedicine*, **2020**, 56, 102796	8.8	1
7	ACTR-39. TWO-YEAR RESULTS OF THE INTELLANCE 2/EORTC TRIAL 1410 RANDOMIZED PHASE II STUDY ON DEPATUXTM ALONE, DEPATUX-M COMBINED WITH TEMOZOLOMIDE (TMZ) AND EITHER TMZ OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA (NCT02343406. *Neuro-Oncology*, **2018**, 20, vi20-vi20	1	1
6	The Erasmus Glioma Database (EGD): Structural MRI scans, WHO 2016 subtypes, and segmentations of 774 patients with glioma. *Data in Brief*, **2021**, 37, 107191	1.2	1
5	The epigenetic evolution of gliomas is determined by their IDH1 mutation status and treatment regimen		1
4	Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas.. *Neuro-Oncology Advances*, **2022**, 4, vdab177	0.9	0
3	Human branching cholangiocyte organoids recapitulate functional bile duct formation.. *Cell Stem Cell*, **2022**, 29, 776-794.e13	18	0
2	Molecular Subtypes of Gliomas **2011**, 25-29		
1	TMOD-19. FROM PATIENT TO PETRI DISH: INCREASING PATIENT-DERIVED GLIOBLASTOMA CULTURE EFFICIENCIES TO 95%. *Neuro-Oncology*, **2021**, 23, vi219-vi219	1	